Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2019 - 2026)
Compass Therapeutics (CMPX) posted Depreciation & Amortization (CF) of $15000.0 for Q1 2026, down 11.76% sequentially from $17000.0 in Q4 2025, and down 89.29% YoY from $140000.0 in Q1 2025.
Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Compass Therapeutics has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $15000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 89.29% year-over-year to $15000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151000.0 (down 73.74% YoY) and the FY2025 annual result came in at $276000.0, down 53.14% from the prior year.
- Depreciation & Amortization (CF) slipped to $15000.0 in Q1 2026 per CMPX's latest filing, from $17000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $220000.0 in Q2 2022 and troughed at $15000.0 in Q1 2026.
- A 5-year average of $138882.4 and a median of $154000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) surged 57.26% in 2022, then tumbled 89.29% in 2026.
- Over 5 years, Depreciation & Amortization (CF) stood at $195000.0 in 2022, then fell by 17.44% to $161000.0 in 2023, then retreated by 13.04% to $140000.0 in 2024, then slumped by 87.86% to $17000.0 in 2025, then dropped by 11.76% to $15000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $15000.0, $17000.0, and $19000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21,000.00 |
| Jun 30, 2026 | 21,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 152,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Mar 31, 2024 | 154,000.00 |